Focus: MyOme is a genomic analysis biotechnology company focused on developing risk assessment tools and diagnostic solutions for neurology, cardiovascular, and rare disease indications. The company operates from Palo Alto with a lean, research-focused team.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Growing — net +5 jobs in 30d
8 jobs added vs 3 removed. Steady team buildout.
MyOme is a high-risk, early-stage genomics play suitable only for risk-tolerant professionals seeking equity upside and scientific autonomy, not career stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for MyOme
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from MyOme's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles